Compare Novavax Inc (NVAX) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Novavax Inc trades at $7.97 (market cap $1.31B), while Vanguard S&P 500 Growth Index Fund ETF trades at $85. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | VOOG | |
|---|---|---|
Market Cap | $1.31B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $11.19 | $85.42 |
52-Week Low | $6.22 | $65.32 |
Enterprise Value | $889.30M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
VOOG trades at $85.05, down 0.18% on the day but near 52-week highs, with a bullish technical signal from moving averages and a neutral oscillator stance. Recent news highlights institutional accumulation and strong growth ETF comparisons, though RSI levels suggest potential overbought conditions. The fund focuses on large-cap growth stocks with low expense ratios, benefiting from tech sector leadership.
Outlook remains positive due to institutional inflows and growth exposure, but risks include tech concentration and market volatility. The fund's low costs and historical performance support long-term growth appeal, though investors should monitor valuation metrics amid elevated levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
